PaxSafe's Mark Talens on why pharma supply chain AI fails before it starts — and the data foundry framework that changes that.
|Articles|October 1, 2015
National Biologics Manufacturing Center Launched in UK
October 01, 2015.
Advertisement
Instigated as part of the Strategy for Life Science, the new £38m ($57.5m) National Biologics Manufacturing Centre opened in Darlington, UK, today.
The Centre is built around six core themes to help companies of all sizes translate their ideas, research and knowledge into commercial business propositions. It will provide companies with open access facilities and expertise to help them develop, prove and commercialize new and improved processes and technologies for biologics manufacture.
Launching the Centre, Jo Johnson MP, Minister of State for Universities and Science said, “We want the UK to be the best place in Europe to innovate ... [T]he Centre will bridge the gap between business and academia and help to turn great ideas into commercial reality.”
Advertisement
Related to this article
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
Why purpose is becoming the most important infrastructure in AI-driven health care technology.
Advertisement
Advertisement
Trending on PharmExec
1
The Impact That the Renewed Focus on Domestic Manufacturing Might Have on the Supply Chain
2
AstraZeneca Taps insitro AI for MASH in Deal Worth Up to $1.5 Billion
3
Pharmaceutical Executive Daily: Gilead Enters $1.87 Billion Collaboration and License Agreement with Vir Biotechnology
4
FDA Launches Rare Disease Framework Initiative
5